|
|
Arsenic in the treatment of newly diagnosed acute promyelocytic leukemia: current status and future research direction |
Jiong HU() |
Department of Hematology, Rui Jin Hospital, Shanghai Institute of Hematology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China |
|
|
Abstract Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia. In past decades, intensive studies on the biology and treatment of this disease have resulted in a remarkably thorough understanding of its pathogenesis and improvement of treatment outcomes. In particular, the introduction of all-trans retinoic acid to conventional chemotherapy improved dramatically the remission and survival rates of APL patients and consequently became the major treatment modality for it. In the last decade, the groundbreaking development of arsenic further improved the survival rate of APL patients. As the most active agent in APL, arsenic directly degrades the PML-RARα fusion transcript, leading to the differentiation and apoptosis of leukemia cells and the potential eradication of APL leukemia-initiating cells (LICs), thus making the disease a potentially curable type of leukemia. More notably, the recent development of oral arsenic compounds may further enhance not only clinical outcomes but also the convenience of patients, which may dramatically change the APL clinical scenario in the near future.
|
Keywords
acute promyelocytic leukemia
arsenic
all-trans retinoic acid
survival
|
Corresponding Author(s):
HU Jiong,Email:hujiong@medmail.com.cn
|
Issue Date: 05 March 2011
|
|
1 |
Rowley J D, Golomb H M, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet , 1977, 1(8010): 549–550 doi: 10.1016/S0140-6736(77)91415-5 pmid:65649
|
2 |
Rousselot P, Hardas B, Patel A, Guidez F, G?ken J, Castaigne S, Dejean A, de Thé H, Degos L, Farzaneh F, .The PML-RAR alpha gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells. Oncogene , 1994, 9(2): 545–551 pmid:8290265
|
3 |
Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood , 2008, 111(5):2505–2515
|
4 |
Huang M E, Ye Y C, Chen S R, Chai J R, Lu J X, Zhoa L, Gu L J, Wang Z Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood , 1988, 72(2): 567–572 pmid:3165295
|
5 |
Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood , 1990, 75(11): 2112–2117 pmid:2189506
|
6 |
Sanz M A, Martín G, Rayón C, Esteve J, González M, Díaz-Mediavilla J, Bolufer P, Barragán E, Terol M J, González J D, Colomer D, Chillón C, Rivas C, Gómez T, Ribera J M, Bornstein R, Román J, Calasanz M J, Arias J, Alvarez C, Ramos F, Debén G. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood , 1999, 94(9): 3015–3021 pmid:10556184
|
7 |
Kelaidi C, Chevret S, De Botton S, Raffoux E, Guerci A, Thomas X, Pigneux A, Lamy T, Rigal-Huguet F, Meyer-Monard S, Chevallier P, Maloisel F, Deconinck E, Ferrant A, Fegueux N, Ifrah N, Sanz M, Dombret H, Fenaux P, Adès L. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol , 2009, 27(16): 2668–2676 doi: 10.1200/JCO.2008.18.4119 pmid:19414681
|
8 |
Tallman M S, Altman J K. How I treat acute promyelocytic leukemia. Blood , 2009, 114(25): 5126–5135 doi: 10.1182/blood-2009-07-216457 pmid:19797519
|
9 |
Shen Z X, Chen G Q, Ni J H, Li X S, Xiong S M, Qiu Q Y, Zhu J, Tang W, Sun G L, Yang K Q, Chen Y, Zhou L, Fang Z W, Wang Y T, Ma J, Zhang P, Zhang T D, Chen S J, Chen Z, Wang Z Y. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood , 1997, 89(9): 3354–3360 pmid:9129042
|
10 |
Chen G Q, Zhu J, Shi X G, Ni J H, Zhong H J, Si G Y, Jin X L, Tang W, Li X S, Xong S M, Shen Z X, Sun G L, Ma J, Zhang P, Zhang T D, Gazin C, Naoe T, Chen S J, Wang Z Y, Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood , 1996, 88(3): 1052–1061 pmid:8704214
|
11 |
Niu C, Yan H, Yu T, Sun H P, Liu J X, Li X S, Wu W, Zhang F Q, Chen Y, Zhou L, Li J M, Zeng X Y, Yang R R, Yuan M M, Ren M Y, Gu F Y, Cao Q, Gu B W, Su X Y, Chen G Q, Xiong S M, Zhang T D, Waxman S, Wang Z Y, Chen Z, Hu J, Shen Z X, Chen S J. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood , 1999, 94(10): 3315–3324 pmid:10552940
|
12 |
Soignet S L, Frankel S R, Douer D, Tallman M S, Kantarjian H, Calleja E, Stone R M, Kalaycio M, Scheinberg D A, Steinherz P, Sievers E L, Coutré S, Dahlberg S, Ellison R, Warrell R P Jr. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol , 2001, 19(18): 3852–3860 pmid:11559723
|
13 |
Mathews V, George B, Lakshmi K M, Viswabandya A, Bajel A, Balasubramanian P, Shaji R V, Srivastava V M, Srivastava A, Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood , 2006, 107(7): 2627–2632 doi: 10.1182/blood-2005-08-3532 pmid:16352810
|
14 |
Mathews V, George B, Chendamarai E, Lakshmi K M, Desire S, Balasubramanian P, Viswabandya A, Thirugnanam R, Abraham A, Shaji R V, Srivastava A, Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol , 2010, 28(24): 3866–3871 doi: 10.1200/JCO.2010.28.5031 pmid:20644086
|
15 |
Ghavamzadeh A, Alimoghaddam K, Ghaffari S H, Rostami S, Jahani M, Hosseini R, Mossavi A, Baybordi E, Khodabadeh A, Iravani M, Bahar B, Mortazavi Y, Totonchi M, Aghdami N. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol , 2006, 17(1): 131–134 doi: 10.1093/annonc/mdj019 pmid:16227315
|
16 |
Zhang P, Wang S, Hu L, Qiu F, Yang H, Xiao Y, Li X, Han X, Zhou J, Liu P. Seven years' summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide-an analysis of 242 cases. Chin J Hematol , 2000, 21(2): 67–70
|
17 |
Zhou G B, Zhang J, Wang Z Y, Chen S J, Chen Z. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc Lond B Biol Sci , 2007, 362(1482): 959–971 17317642 doi: 10.1098/rstb.2007.2026
|
18 |
Lallemand-Breitenbach V, Guillemin M C, Janin A, Daniel M T, Degos L, Kogan S C, Bishop J M, de Thé H. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med , 1999, 189(7): 1043–1052 doi: 10.1084/jem.189.7.1043 pmid:10190895
|
19 |
Jing Y, Wang L, Xia L, Chen G Q, Chen Z, Miller W H, Waxman S. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood , 2001, 97(1): 264–269 doi: 10.1182/blood.V97.1.264 pmid:11133770
|
20 |
Raffoux E, Rousselot P, Poupon J, Daniel M T, Cassinat B, Delarue R, Taksin A L, Réa D, Buzyn A, Tibi A, Lebbé G, Cimerman P, Chomienne C, Fermand J P, de Thé H, Degos L, Hermine O, Dombret H. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol , 2003, 21(12): 2326–2334 doi: 10.1200/JCO.2003.01.149 pmid:12805334
|
21 |
Shen Z X, Shi Z Z, Fang J, Gu B W, Li J M, Zhu Y M, Shi J Y, Zheng P Z, Yan H, Liu Y F, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De Thé H, Wang Z Y, Chen S J, Chen Z. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA , 2004, 101(15): 5328–5335 doi: 10.1073/pnas.0400053101 pmid:15044693
|
22 |
Hu J, Liu Y F, Wu C F, Xu F, Shen Z X, Zhu Y M, Li J M, Tang W, Zhao W L, Wu W, Sun H P, Chen Q S, Chen B, Zhou G B, Zelent A, Waxman S, Wang Z Y, Chen S J, Chen Z. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA , 2009, 106(9): 3342–3347 doi: 10.1073/pnas.0813280106 pmid:19225113
|
23 |
Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood , 2006, 107(9): 3469–3473 doi: 10.1182/blood-2005-10-4006 pmid:16373661
|
24 |
Ravandi F, Estey E, Jones D, Faderl S, O’Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol , 2009, 27(4): 504–510 doi: 10.1200/JCO.2008.18.6130 pmid:19075265
|
25 |
Powell B L, Moser B, Stock W, Gallagher R E, Willman C L, Stone R M, Rowe J M, Coutre S, Feusner J H, Gregory J, Couban S, Appelbaum F R, Tallman M S, Larson R A. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood , 2010, 116(19): 3751–3757 doi: 10.1182/blood-2010-02-269621 pmid:20705755
|
26 |
Sanz M A, Grimwade D, Tallman M S, Lowenberg B, Fenaux P, Estey E H, Naoe T, Lengfelder E, Büchner T, D?hner H, Burnett A K, Lo-Coco F. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood , 2009, 113(9): 1875–1891 doi: 10.1182/blood-2008-04-150250 pmid:18812465
|
27 |
Zhu J, Lallemand-Breitenbach V, de Thé H. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene , 2001, 20(49): 7257–7265 doi: 10.1038/sj.onc.1204852 pmid:11704854
|
28 |
Zhu J, Zhou J, Peres L, Riaucoux F, Honoré N, Kogan S, de Thé H. A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell , 2005, 7(2): 143–153 doi: 10.1016/j.ccr.2005.01.005 pmid:15710327
|
29 |
Lallemand-Breitenbach V, Zhu J, Puvion F, Koken M, Honoré N, Doubeikovsky A, Duprez E, Pandolfi P P, Puvion E, Freemont P, de Thé H. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med , 2001, 193(12): 1361–1371 doi: 10.1084/jem.193.12.1361 pmid:11413191
|
30 |
Zhang X W, Yan X J, Zhou Z R, Yang F F, Wu Z Y, Sun H B, Liang W X, Song A X, Lallemand-Breitenbach V, Jeanne M, Zhang Q Y, Yang H Y, Huang Q H, Zhou G B, Tong J H, Zhang Y, Wu J H, Hu H Y, de Thé H, Chen S J, Chen Z. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science , 2010, 328(5975): 240–243 doi: 10.1126/science.1183424 pmid:20378816
|
31 |
Nasr R, Lallemand-Breitenbach V, Zhu J, Guillemin M C, de Thé H. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Clin Cancer Res , 2009, 15(20): 6321–6326 doi: 10.1158/1078-0432.CCR-09-0209 pmid:19808868
|
32 |
Wang J C, Dick J E. Cancer stem cells: lessons from leukemia. Trends Cell Biol , 2005, 15(9): 494–501 doi: 10.1016/j.tcb.2005.07.004 pmid:16084092
|
33 |
Grignani F, Ferrucci P F, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C, Nicoletti I, .The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell , 1993, 74(3): 423–431 doi: 10.1016/0092-8674(93)80044-F pmid:8394219
|
34 |
Du C, Redner R L, Cooke M P, Lavau C. Overexpression of wild-type retinoic acid receptor alpha (RARalpha) recapitulates retinoic acid-sensitive transformation of primary myeloid progenitors by acute promyelocytic leukemia RARalpha-fusion genes. Blood , 1999, 94(2): 793–802 pmid:10397747
|
35 |
Nasr R, Guillemin M C, Ferhi O, Soilihi H, Peres L, Berthier C, Rousselot P, Robledo-Sarmiento M, Lallemand-Breitenbach V, Gourmel B, Vitoux D, Pandolfi P P, Rochette-Egly C, Zhu J, de Thé H. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med , 2008, 14(12): 1333–1342 doi: 10.1038/nm.1891 pmid:19029980
|
36 |
Delva L, Cornic M, Balitrand N, Guidez F, Micléa J M, Delmer A, Teillet F, Fenaux P, Castaigne S, Degos L, .Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood , 1993, 82(7): 2175–2181 pmid:8400267
|
37 |
Zheng X, Seshire A, Rüster B, Bug G, Beissert T, Puccetti E, Hoelzer D, Henschler R, Ruthardt M. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haematologica , 2007, 92(3): 323–331 doi: 10.3324/haematol.10541 pmid:17339181
|
38 |
Kogan S C. Curing APL: differentiation or destruction? Cancer Cell , 2009, 15(1): 7–8 doi: 10.1016/j.ccr.2008.12.012 pmid:19111876
|
39 |
Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, Rosenblatt J, Avigan D E, Teruya-Feldstein J, Pandolfi P P. PML targeting eradicates quiescent leukaemia-initiating cells. Nature , 2008, 453(7198): 1072–1078 doi: 10.1038/nature07016 pmid:18469801
|
40 |
Luesink M, Pennings J L, Wissink W M, Linssen P C, Muus P, Pfundt R, de Witte T J, van der Reijden B A, Jansen J H. Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood , 2009, 114(27): 5512–5521 doi: 10.1182/blood-2009-02-204834 pmid:19828696
|
41 |
Tallman M S, Andersen J W, Schiffer C A, Appelbaum F R, Feusner J H, Ogden A, Shepherd L, Rowe J M, Fran?ois C, Larson R S, Wiernik P H. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood , 2000, 95(1): 90–95 pmid:10607690
|
42 |
Ng J C, Wang J, Shraim A. A global health problem caused by arsenic from natural sources. Chemosphere , 2003, 52(9): 1353–1359 doi: 10.1016/S0045-6535(03)00470-3 pmid:12867164
|
43 |
Ficker E, Kuryshev Y A, Dennis A T, Obejero-Paz C, Wang L, Hawryluk P, Wible B A, Brown A M. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol , 2004, 66(1): 33–44 doi: 10.1124/mol.66.1.33 pmid:15213294
|
44 |
Kojima C, Ramirez D C, Tokar E J, Himeno S, Drobná Z, Styblo M, Mason R P, Waalkes M P. Requirement of arsenic biomethylation for oxidative DNA damage. J Natl Cancer Inst , 2009, 101(24): 1670–1681 doi: 10.1093/jnci/djp414 pmid:19933942
|
45 |
Hughes M F. Arsenic methylation, oxidative stress and cancer—is there a link? J Natl Cancer Inst , 2009, 101(24): 1660–1661 doi: 10.1093/jnci/djp437 pmid:19933940
|
46 |
Lu D P, Qiu J Y, Jiang B, Wang Q, Liu K Y, Liu Y R, Chen S S. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood , 2002, 99(9): 3136–3143 doi: 10.1182/blood.V99.9.3136 pmid:11964275
|
47 |
The Cooperation Group of Phase II Clinical Trial of Compound Huangdai Tablet. Phase II clinical trial of compound Huangdai tablet in newly diagnosed acute promyelocytic leukemia. Chin J Hematol , 2006, 27(12): 801–804
|
48 |
Sun F, Chen N N, Cheng Y B. Compound realgar and natural indigo tablets in treatment of acute promyelocytic leukemia: a summary of experience in 204 cases. Zhong Xi Yi Jie He Xue Bao , 2008, 6(6): 639–642 doi: 10.3736/jcim20080618 pmid:18559245
|
49 |
Au W Y, Kumana C R, Kou M, Mak R, Chan G C, Lam C W, Kwong Y L. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood , 2003, 102(1): 407–408 doi: 10.1182/blood-2003-01-0298 pmid:12814916
|
50 |
Siu C W, Au W Y, Yung C, Kumana C R, Lau C P, Kwong Y L, Tse H F. Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety. Blood , 2006, 108(1): 103–106 doi: 10.1182/blood-2006-01-0054 pmid:16514059
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|